Prediction of an excessive response in in vitro fertilization from patient characteristics and ovarian reserve tests and comparison in subgroups: an individual patient data meta-analysis.

[1]  B. Mol,et al.  The OPTIMIST study: optimisation of cost effectiveness through individualised FSH stimulation dosages for IVF treatment. A randomised controlled trial , 2012, BMC Women's Health.

[2]  E. Anckaert,et al.  The value of anti-Müllerian hormone measurement in the long GnRH agonist protocol: association with ovarian response and gonadotrophin-dose adjustments , 2012, Human reproduction.

[3]  K. Gordon,et al.  Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pre-treatment. , 2011, Human reproduction.

[4]  Susan Mallett,et al.  QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies , 2011, Annals of Internal Medicine.

[5]  B. Mol,et al.  Cost effectiveness of ovarian reserve testing in in vitro fertilization: a Markov decision-analytic model. , 2011, Fertility and sterility.

[6]  Sesh Kamal Sunkara,et al.  Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. , 2011, Human reproduction.

[7]  S. Broer.  Assessment of current and future ovarian reserve status , 2011 .

[8]  M. Eijkemans,et al.  Anti-mullerian hormone predicts menopause: a long-term follow-up study in normoovulatory women. , 2011, The Journal of clinical endocrinology and metabolism.

[9]  K. Oktay,et al.  Anti-Mullerian hormone and antral follicle count as predictors for embryo/oocyte cryopreservation cycle outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone , 2011, Journal of Assisted Reproduction and Genetics.

[10]  B. Mol,et al.  Are patient characteristics associated with the accuracy of hysterosalpingography in diagnosing tubal pathology? An individual patient data meta-analysis. , 2011, Human reproduction update.

[11]  M. Eijkemans,et al.  Clinical outcomes in relation to the daily dose of recombinant follicle-stimulating hormone for ovarian stimulation in in vitro fertilization in presumed normal responders younger than 39 years: a meta-analysis. , 2011, Human reproduction update.

[12]  F. Broekmans,et al.  AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis. , 2011, Human reproduction update.

[13]  S. Oehninger,et al.  Anti-Müllerian hormone serum levels predict response to controlled ovarian hyperstimulation but not embryo quality or pregnancy outcome in oocyte donation. , 2011, Fertility and sterility.

[14]  M. Sauer,et al.  Anti-Müllerian hormone testing is useful for individualization of stimulation protocols in oocyte donors. , 2011, Reproductive biomedicine online.

[15]  B. Mol,et al.  The role of anti-Müllerian hormone assessment in assisted reproductive technology outcome , 2010, Current opinion in obstetrics & gynecology.

[16]  N. Raine-Fenning,et al.  A randomised controlled trial of 300 versus 225 IU recombinant FSH for ovarian stimulation in predicted normal responders by antral follicle count , 2010, BJOG : an international journal of obstetrics and gynaecology.

[17]  J. Dungan.  Circulating basal anti-Müllerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization , 2010 .

[18]  A. Aflatoonian,et al.  Prediction of high ovarian response to controlled ovarian hyperstimulation: anti-Müllerian hormone versus small antral follicle count (2–6 mm) , 2009, Journal of Assisted Reproduction and Genetics.

[19]  Lucas M Bachmann,et al.  Individual patient data meta-analysis of diagnostic and prognostic studies in obstetrics, gynaecology and reproductive medicine , 2009, BMC medical research methodology.

[20]  Gary Longton,et al.  Accommodating Covariates in Receiver Operating Characteristic Analysis , 2009 .

[21]  B. Mol,et al.  The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. , 2009, Fertility and sterility.

[22]  Gary Longton,et al.  Estimation and Comparison of Receiver Operating Characteristic Curves , 2009, The Stata journal.

[23]  M. Eijkemans,et al.  The clinical significance of the retrieval of a low number of oocytes following mild ovarian stimulation for IVF: a meta-analysis. , 2008, Human reproduction update.

[24]  M. Wikland,et al.  Individualizing FSH dose for assisted reproduction using a novel algorithm: the CONSORT study. , 2009, Reproductive biomedicine online.

[25]  Gary Longton,et al.  Accommodating Covariates in ROC Analysis. , 2009, The Stata journal.

[26]  Richard D Riley,et al.  Meta‐analysis of diagnostic test studies using individual patient data and aggregate data , 2008, Statistics in medicine.

[27]  E. Greenblatt,et al.  Elevated day 3 follicle-stimulating hormone/luteinizing hormone ratio >or= 2 is associated with higher rates of cancellation in in vitro fertilization-embryo transfer cycles. , 2008, Fertility and sterility.

[28]  B. Leader,et al.  Assessment of ovarian reserve with anti-Müllerian hormone: a comparison of the predictive value of anti-Müllerian hormone, follicle-stimulating hormone, inhibin B, and age. , 2008, American journal of obstetrics and gynecology.

[29]  E Godehardt,et al.  Relevance of anti-Mullerian hormone measurement in a routine IVF program. , 2008, Human reproduction.

[30]  P. Devroey,et al.  Predictors of ovarian response: progress towards individualized treatment in ovulation induction and ovarian stimulation. , 2008, Human reproduction update.

[31]  S. Nelson,et al.  Serum anti-Müllerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles--implications for individualization of therapy. , 2007, Human reproduction.

[32]  B K Campbell,et al.  Does 3D ultrasound offer any advantage in the pretreatment assessment of ovarian reserve and prediction of outcome after assisted reproduction treatment? , 2007, Human reproduction.

[33]  L. Merce,et al.  Prediction of ovarian response and IVF/ICSI outcome by three-dimensional ultrasonography and power Doppler angiography. , 2007, European journal of obstetrics, gynecology, and reproductive biology.

[34]  T. Mukherjee,et al.  Moderately elevated levels of basal follicle-stimulating hormone in young patients predict low ovarian response, but should not be used to disqualify patients from attempting in vitro fertilization. , 2007, Fertility and sterility.

[35]  Jan Passchier,et al.  A mild treatment strategy for in-vitro fertilisation: a randomised non-inferiority trial , 2007, The Lancet.

[36]  A. Volpe,et al.  Anti-Müllerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. , 2007, Human reproduction.

[37]  J. Skull,et al.  Evaluation of the utility of multiple endocrine and ultrasound measures of ovarian reserve in the prediction of cycle cancellation in a high-risk IVF population. , 2007, Human reproduction.

[38]  M. Denis,et al.  Measurement of serum anti-Müllerian hormone by Beckman Coulter ELISA and DSL ELISA: comparison and relevance in assisted reproduction technology (ART). , 2007, Clinica chimica acta; international journal of clinical chemistry.

[39]  G. Zielhuis,et al.  Antimüllerian hormone predicts ovarian responsiveness, but not embryo quality or pregnancy, after in vitro fertilization or intracyoplasmic sperm injection. , 2007, Fertility and sterility.

[40]  B. Mol,et al.  A systematic review of tests predicting ovarian reserve and IVF outcome. , 2006, Human reproduction update.

[41]  O. Shebl,et al.  Basal level of anti-Müllerian hormone is associated with oocyte quality in stimulated cycles. , 2006, Human reproduction.

[42]  Jeff G. Wang,et al.  Elevated serum müllerian-inhibiting substance may be a marker for ovarian hyperstimulation syndrome in normal women undergoing in vitro fertilization. , 2006, Fertility and sterility.

[43]  M. Eijkemans,et al.  Optimum number of oocytes for a successful first IVF treatment cycle. , 2006, Reproductive biomedicine online.

[44]  M. Matteo,et al.  Basal FSH concentration as a predictor of IVF outcome in older women undergoing stimulation with GnRH antagonist. , 2006, Reproductive biomedicine online.

[45]  B. Fauser,et al.  Preimplantation genetic screening reveals a high incidence of aneuploidy and mosaicism in embryos from young women undergoing IVF. , 2006, Human reproduction.

[46]  E. Margalioth,et al.  Dynamic assays of inhibin B, anti-Mullerian hormone and estradiol following FSH stimulation and ovarian ultrasonography as predictors of IVF outcome , 2005 .

[47]  P. Serhal,et al.  Antral follicle count, anti‐mullerian hormone and inhibin B: predictors of ovarian response in assisted reproductive technology? , 2005, BJOG : an international journal of obstetrics and gynaecology.

[48]  M. Ashrafi,et al.  Follicle stimulating hormone as a predictor of ovarian response in women undergoing controlled ovarian hyperstimulation for IVF , 2005, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[49]  W. Yeung,et al.  The significance of antral follicle count in controlled ovarian stimulation and intrauterine insemination , 2005, Journal of Assisted Reproduction and Genetics.

[50]  P. Ho,et al.  Antral follicle count and FSH concentration after clomiphene citrate challenge test in the prediction of ovarian response during IVF treatment. , 2005, Human reproduction.

[51]  E. Badings,et al.  Obesity and Clomiphene Challenge Test as Predictors of Outcome of in vitro Fertilization and Intracytoplasmic Sperm Injection , 2005, Gynecologic and Obstetric Investigation.

[52]  J. Habbema,et al.  The antral follicle count is a better marker than basal follicle-stimulating hormone for the selection of older patients with acceptable pregnancy prospects after in vitro fertilization. , 2005, Fertility and sterility.

[53]  A. Ivanova,et al.  Prognostic value of some ovarian reserve tests in poor responders , 2005, Archives of Gynecology and Obstetrics.

[54]  S. Muttukrishna,et al.  Inhibin B and anti‐Mullerian hormone: markers of ovarian response in IVF/ICSI patients? , 2004, BJOG : an international journal of obstetrics and gynaecology.

[55]  K. Biberoğlu,et al.  Comparison of Basal and Clomiphene Citrate Induced FSH and Inhibin B, Ovarian Volume and Antral Follicle Counts as Ovarian Reserve Tests and Predictors of Poor Ovarian Response in IVF , 2004, Journal of Assisted Reproduction and Genetics.

[56]  Y. Hwu,et al.  Estradiol Level on Day 9 as a Predictor of Risk for Ovarian Hyperresponse During Controlled Ovarian Hyperstimulation , 2003, Journal of Assisted Reproduction and Genetics.

[57]  A. Loft,et al.  A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a 'standard' dose of 150 IU/day in 'standard' patients undergoing IVF/ICSI treatment. , 2003, Human reproduction.

[58]  P. Bezemer,et al.  Comparison of endocrine tests with respect to their predictive value on the outcome of ovarian hyperstimulation in IVF treatment: results of a prospective randomized study. , 2003, Human reproduction.

[59]  M. Steinkampf,et al.  Effect of obesity on recombinant follicle-stimulating hormone absorption: subcutaneous versus intramuscular administration. , 2003, Fertility and sterility.

[60]  A. Andersson,et al.  A prospective study of predictive factors of ovarian response in 'standard' IVF/ICSI patients treated with recombinant FSH. A suggestion for a recombinant FSH dosage normogram. , 2003, Human reproduction.

[61]  D. Tacheva,et al.  [Prognostic value of some hormonal and ultrasound ovarian reserve tests]. , 2003, Akusherstvo i ginekologiia.

[62]  D. Baird,et al.  Prospective analysis of the relationships between the ovarian follicle cohort and basal FSH concentration, the inhibin response to exogenous FSH and ovarian follicle number at different stages of the normal menstrual cycle and after pituitary down-regulation. , 2003, Human reproduction.

[63]  F. Broekmans,et al.  Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve. , 2002, Human reproduction.

[64]  Serge Rozenberg,et al.  Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. , 2002, Human reproduction update.

[65]  J. Kremer,et al.  External validation of the templeton model for predicting success after IVF. , 2000, Human reproduction.

[66]  M. Blankenstein,et al.  Basal follicle-stimulating hormone levels are of limited value in predicting ongoing pregnancy rates after in vitro fertilization. , 2000, Fertility and sterility.

[67]  J. Schoemaker,et al.  Cohort size rather than follicle-stimulating hormone threshold level determines ovarian sensitivity in polycystic ovary syndrome. , 1998, The Journal of clinical endocrinology and metabolism.

[68]  H. Martikainen,et al.  Pretreatment transvaginal ultrasound examination predicts ovarian responsiveness to gonadotrophins in in-vitro fertilization. , 1997, Human reproduction.